Uncategorized
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
BeiGene Scores Two Major FDA Approvals – Trivimbra for Esophageal Cancer and Brukinsa for Follicular Lymphoma
BeiGene, Trivimbra (tislelizumab), Esophageal Cancer, Brukinsa (zanubrutinib), Follicular Lymphoma, FDA Approval, Accelerated Approval, Obinutuzumab
Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.
Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction
Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy
Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment
Brukinsa Broadens Horizons: FDA Clears Follicular Lymphoma Combination Therapy
Brukinsa, Follicular lymphoma, FDA approval, BTK inhibitor, BTK inhibitor, Broadest label, Relapsed or refractory follicular lymphoma, ROSEWOOD Phase II study, CHMP positive opinion, Obinutuzumab combination therapy, Accelerated approval, Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma, Chronic lymphoma, CHMP recommendation, Phase II ROSEWOOD trial, Overall response rate (OR
Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO
Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024
Merck KGaA Abandons BTK Inhibitor Program, Emphasizes External Innovation
Merck KGaA, BTK inhibitor, Evobrutinib, External innovation strategy, Failed clinical trials
GSK Boosts Blenrep’s Resurgence with Successful Second Phase III Trial
– **Company**: GlaxoSmithKline (GSK) – **Product**: Blenrep – **News**: Positive data reported from a second Phase III clinical trial for Blenrep – **Comeback Potential**: This news suggests a potential rebound for Blenrep, which previously faced setbacks – **Date**: Information released on March 15, 2024
Boundless Bio Joins 2024 IPO Surge Amidst Prominent Oncology Trial Outcomes
Boundless Bio, Initial Public Offering (IPO), Cancer-focused biotech, 2024 IPO rally, Oncology trials, Clinical data readouts
Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline
NBD1 stabilizers, ICL4 inhibitor, Cystic fibrosis, CFTR, NBD1, Cystic fibrosis, Cystic fibrosis, Sionna, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic Cystic, Cystic Cystic Cystic:, Search for the citation: